Pfizer's JAK3 inhibitor notches up more positive Phase II data in RA
This article was originally published in Scrip
Executive Summary
Two Phase II trials of Pfizer's JAK3 inhibitor CP-690550 show the drug is safe and effective as both monotherapy and combination therapy with methotrexate for the treatment of rheumatoid arthritis (RA).